Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615804 | 1.00 | CNR2 (0.32) | CNR2RENCYP3A4FEN1NAMPT | |
| SCHEMBL4975133 | 1.00 | CNR2 (0.32) | CNR2RENCYP3A4FEN1NAMPT | |
| SCHEMBL3615805 | 1.00 | CNR2 (0.32) | CNR2RENCYP3A4FEN1NAMPT | |
| SCHEMBL26126004 | 1.00 | CNR2 (0.32) | CNR2RENCYP3A4FEN1NAMPT | |
| SCHEMBL3604264 | 0.95 | CNR2 (0.32) | CNR2 | |
| SCHEMBL3619395 | 0.91 | — | — | |
| SCHEMBL3619393 | 0.91 | — | — | |
| SCHEMBL4071173 | 0.87 | CYP2D6 (0.33) | RENFEN1 | |
| SCHEMBL2027347 | 0.87 | CYP2D6 (0.33) | RENFEN1 | |
| SCHEMBL2330185 | 0.84 | REN (0.40) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2074108-B3 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2581366-A1 | Renin Inhibitors | Vitae Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2074108-B1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8198453-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100190829-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC | 2010-07-29 | — | — | US | disclosed |
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090312369-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS , INC. | 2009-12-17 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | CNR2 4640/4885REN 180/4885CYP3A4 2510/4885 |
| US-20100190829-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | CNR2 4689/4885REN 2/4885CYP3A4 3133/4885 |
| US-20100184805-A1 | RENIN INHIBITORS | ACE, REN, ACE2 | CNR2 4746/4885REN 2/4885CYP3A4 1357/4885 |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | ACE, PEPD, DNPEP | CNR2 4077/4885REN 4/4885CYP3A4 2584/4885 |
| US-20100160424-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | CNR2 4689/4885REN 2/4885CYP3A4 3133/4885 |
| US-20090312369-A1 | Renin Inhibitors | ACE, REN, DNPEP | CNR2 4534/4885REN 2/4885CYP3A4 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.